Literature DB >> 7587102

The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.

K M Dameron1, O V Volpert, M A Tainsky, N Bouck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7587102     DOI： 10.1101/sqb.1994.059.01.053

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN： 0091-7451


× No keyword cloud information.
  26 in total

1.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway.

Authors:  M Tan; Y Wang; K Guan; Y Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs.

Authors:  Z Miner; M Kulesz-Martin
Journal:  Nucleic Acids Res       Date:  1997-04-01       Impact factor: 16.971

Review 3.  Molecular mechanisms of tumor angiogenesis and tumor progression.

Authors:  U Cavallaro; G Christofori
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

Authors:  O V Volpert; J Lawler; N P Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 5.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

6.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

Review 7.  Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

Authors:  Tanya A Rege; Constance Y Fears; Candece L Gladson
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

8.  Antiangiogenic Gene Therapy in Cancer.

Authors:  L Zhang; Q R Chen; A J Mixson
Journal:  Curr Genomics       Date:  2000       Impact factor: 2.236

Review 9.  Contribution of p53 to metastasis.

Authors:  Emily Powell; David Piwnica-Worms; Helen Piwnica-Worms
Journal:  Cancer Discov       Date:  2014-03-21       Impact factor: 39.397

10.  Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.

Authors:  S L Maloney; D C Sullivan; S Suchting; J M J Herbert; E M Rabai; Z Nagy; J Barker; S Sundar; R Bicknell
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.